An aminosalicylate medication called mesalazine is used to treat mild to moderate active ulcerative colitis and maintain remission once it has been attained. Mesalazine, an anti-inflammatory medication used to treat inflammatory bowel illnesses like ulcerative colitis and Crohn’s disease, shares structural similarities with salicylates and non-steroidal anti-inflammatory treatments like acetylsalicylic acid. Chronic inflammatory bowel disease known as ulcerative colitis results in inflammation of the lining of the large intestine (colon). It results in ulcers on the lining of the colon, which may result in bleeding, pus discharge, and mucus secretion. Mesalazine reduces inflammation (redness and swelling) in the intestines and relieves symptoms like stomach discomfort by decreasing the formation of specific chemical compounds like prostaglandins that induce pain and swelling.
The market for mesalazine in China is anticipated to reach a value of $51.6 million in 2022 and grow at a CAGR of 3.1% during the following five years (2022-2030).
Click Here To Request Sample Report of the China Mesalazine Market:
https://www.coherentmarketinsights.com/insight/request-sample/5371
Market Drivers:
The expansion of the China mesalazine market is predicted to be fueled by an increase in inorganic methods, such as new releases by major industry participants. For instance, the pharmaceutical company Tillotts Pharma AG introduced Asacol 800 mg tablets (mesalazine) as the primary therapy for mild to severe Ulcerative Colitis (UC) in China in July 2021. To improve the therapeutic choices for patients with ulcerative colitis in China, a stronger formulation of mesalazine tablets will be introduced to the market there.
The World Health Organization declared a public health emergency on January 30, 2020, as a result of the disease’s global expansion after the COVID-19 viral epidemic in December 2019. The disease has now been detected in over 100 countries.
Three key ways that the COVID-19 can effect the economy include directly impacting drug supply and demand, disrupting distribution routes, and having an economic impact on businesses and financial markets. Many nations, including China, India, Saudi Arabia, the United Arab Emirates, Egypt, and others, are having trouble moving pharmaceuticals from one location to another as a result of widespread lockdowns.
The COVID-19 epidemic, however, had a favourable effect on the mesalazine market in China. For instance, the COVID-19 pandemic had a medical and behavioural impact on individuals with inflammatory bowel disease (IBD), according to data from the National Center for Biotechnology Information that was published in May 2020. The majority of IBD patients developed symptoms during the early and present stages of the outbreak; these patients did not need to switch to new drugs.
Key Developments
Joint partnerships between industry participants are anticipated to fuel the growth of the China mesalazine market throughout the forecast period. For instance, the pharmaceutical business Alembic Pharmaceutical Limited declared in November 2022 that the U.S. had approved their product. The Food and Drug Administration (U.S. FDA) has approved the Abbreviated New Drug Application (ANDA) for the 0.375 g strength of Mesalazine Extended-Release Capsules.
For Additional List and Detail Information on Key Players, Send Your Request for PDF Brochure :
https://www.coherentmarketinsights.com/insight/request-pdf/5371
Market Restraint
Over the course of the forecast period, the growth of the China mesalazine market is anticipated to be constrained by the availability of substitutes. The first line of treatment for ulcerative colitis is aminosalicylate (5-ASA). In addition, several drug classes are recommended for the treatment of Crohn’s disease, inflammatory bowel disease, and ulcerative colitis. Corticosteroids, Immunomodulators, Targeted Synthetic Small Molecules (Immunosuppressants), and Biologic/Biosimilar Therapies are some of them (Monoclonal Antibodies). Additionally, the development of biosimilars has completely changed how Ulcerative Colitis is managed (UC). It is a biological therapy for inflammatory bowel diseases (IBD), such as Crohn’s and ulcerative colitis. These medications are more affordable than other medications, making them more available to Chinese citizens.
| ATTRIBUTES | DETAILS |
|---|---|
| Estimated Year | 2022 |
| Base Year | 2021 |
| Forecast Year | 2030 |
| Historical Year | 2017-2020 |
| Unit | Value (USD Million/Billion) |
| Segments Covered | Types, Applications, End-Users, and more. |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| By Region | North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
| Customization Scope | We customize your report according to your research need. Ask our sales team for report customization. |
Directly Purchase This Complete Business Research Report:
https://www.coherentmarketinsights.com/insight/buy-now/5371
Key Players
Dr. Falk Pharma GmbH, ALP Pharm Beijing Co., Ltd., Viatris Inc., Shanghai Pharmaceuticals Holding Co Ltd., FERRING B.V., Heilongjiang Tianhong Pharmaceutical Co., Ltd., Salix Pharmaceuticals, AbbVie Inc., Novartis AG, F. Hoffmann-La Roche AG, GSK Plc, Tillotts Pharma AG, and Takeda Pharmaceuticals Company Limited are major companies that operate in the China.
📌Frequently Asked Questions:
1) What is the potential of the China Mesalazine Market?
2) What are the latest research and activities of the industry?
3) What is the total expected CAGR for the industry?
4) Who are the crucial players operating the market?
5) What are the major market patterns influencing the development of the industry?
6) What is the financial effect on the business and the improvement pattern of the business?
7) Which is the most propelling country in the industry?
8) What are industry dynamics?
Finally, the report determines the sales volumes that will assist the reader in predicting the size of the whole industry. Also, through this report, companies can also forecast the numbers for the crucial sectors with expected categorization by types and end-use industries. Unique graphics and instances of SWOT analysis have been presented. Further, the goal of the study is to provide the best marketing strategies for competitive players with novel technologies, geographical diversification, and new product launches.
Contact us:
Mr. Shah
Coherent Market Insights
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com